Skip to main content

Advertisement

Table 2 Changes in MRI parameters

From: Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study

mITT-LOCF population 24 months    
Chondroitin sulfate Celecoxib p valuea    
(n = 69) (n = 69)    
Cartilage volume loss (%)
Lateral compartment –4.1 ± 3.1 –4.4 ± 3.0 0.814    
 Condyle –3.0 ± 3.1 –4.1 ± 3.7 0.144    
 Plateau –5.8 ± 4.7 –4.8 ± 3.5 0.182    
Medial compartment –6.3 ± 3.2 –8.1 ± 4.2 0.018    
 Condyle –5.5 ± 3.9 –7.7 ± 4.7 0.008    
 Plateau –7.6 ± 4.0 –8.6 ± 4.8 0.276    
Synovial membrane thicknessb (mm) 0.13 ± 0.25 0.14 ± 0.24 0.948    
Synovial fluid volume (ml) –2.6 ± 14.5 –2.0 ± 11.8 0.776    
BML scoreb 1.1 ± 1.7 0.8 ± 1.7 0.322    
ATP population 12 months 24 months
Chondroitin sulfate Celecoxib p valuea Chondroitin sulfate Celecoxib p valuea
(n = 57)c (n = 63) (n = 57)c (n = 63)
Cartilage volume loss (%)
 Lateral compartment –3.4 ± 2.7 –3.3 ± 2.5 0.932 –4.6 ± 3.0 –4.4 ± 2.8 0.753
  Condyle –2.5 ± 3.2 –3.0 ± 3.0 0.234 –3.4 ± 3.0 –4.2 ± 3.6 0.316
  Plateau –4.6 ± 3.5 –3.8 ± 3.1 0.194 –6.3 ± 4.6 –4.8 ± 3.5 0.081
 Medial compartment –4.5 ± 2.6 –5.6 ± 3.0 0.049 –6.6 ± 3.3 –8.4 ± 4.2 0.021
  Condyle –3.8 ± 3.2 –5.0 ± 3.8 0.100 –5.7 ± 4.0 –8.1 ± 4.7 0.010
  Plateau –5.5 ± 3.0 –6.6 ± 3.8 0.155 –8.0 ± 4.2 –9.0 ± 4.8 0.334
Synovial membrane thicknessb (mm) 0.03 ± 0.18 0.06 ± 0.18 0.579 0.15 ± 0.26 0.15 ± 0.24 0.731
Synovial fluid volume (ml) –5.5 ± 12.6 –1.8 ± 9.2 0.326 –3.9 ± 15.4 –2.1 ± 12.2 0.945
BML scoreb 0.7 ± 1.4 0.3 ± 1.2 0.051 1.1 ± 1.7 0.8 ± 1.7 0.322
  1. Data are mean ± standard deviation
  2. aAnalysis of covariance; model includes BMI as covariate; bold indicates statistical significance
  3. bGlobal knee
  4. cAmong the 58 patients in the chondroitin sulfate group who completed the study, one patient did not complete the MRI at 24 months
  5. ATP according-to-protocol, BMI body mass index, BML bone marrow lesion, LOCF last observation carried forward, mITT modified intention-to-treat, MRI magnetic resonance imaging